Advanced search
1 file | 427.88 KB Add to list

Nanomedicine to aid immunogenic cell death (ICD)-based anticancer therapy

Robin Demuynck (UGent) , Yanou Engelen (UGent) , Andre Skirtach (UGent) , Stefaan De Smedt (UGent) , Ine Lentacker (UGent) and Dmitri Krysko (UGent)
(2024) TRENDS IN CANCER. 10(6). p.486-489
Author
Organization
Project
Abstract
Immunogenic cell death (ICD) is emerging as a key component of antitumor therapy that harnesses the immune system of the patient to combat cancer. In recent years, several efforts were made to improve the ICD-based therapies. Here, we discuss how nanomaterial-based strategies increase the efficacy of ICD and highlight their benefits and challenges.
Keywords
DAMPs, anticancer immunity, apoptosis, necroptosis, pyroptosis and ferroptosis nanoparticles, immunogenic cell death, nanomedicine, nanoparticles, nanocapsules, anticancer therapy, cancer, CANCER

Downloads

  • (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • PDF
    • |
    • 427.88 KB

Citation

Please use this url to cite or link to this publication:

MLA
Demuynck, Robin, et al. “Nanomedicine to Aid Immunogenic Cell Death (ICD)-Based Anticancer Therapy.” TRENDS IN CANCER, vol. 10, no. 6, 2024, pp. 486–89, doi:10.1016/j.trecan.2024.03.003.
APA
Demuynck, R., Engelen, Y., Skirtach, A., De Smedt, S., Lentacker, I., & Krysko, D. (2024). Nanomedicine to aid immunogenic cell death (ICD)-based anticancer therapy. TRENDS IN CANCER, 10(6), 486–489. https://doi.org/10.1016/j.trecan.2024.03.003
Chicago author-date
Demuynck, Robin, Yanou Engelen, Andre Skirtach, Stefaan De Smedt, Ine Lentacker, and Dmitri Krysko. 2024. “Nanomedicine to Aid Immunogenic Cell Death (ICD)-Based Anticancer Therapy.” TRENDS IN CANCER 10 (6): 486–89. https://doi.org/10.1016/j.trecan.2024.03.003.
Chicago author-date (all authors)
Demuynck, Robin, Yanou Engelen, Andre Skirtach, Stefaan De Smedt, Ine Lentacker, and Dmitri Krysko. 2024. “Nanomedicine to Aid Immunogenic Cell Death (ICD)-Based Anticancer Therapy.” TRENDS IN CANCER 10 (6): 486–489. doi:10.1016/j.trecan.2024.03.003.
Vancouver
1.
Demuynck R, Engelen Y, Skirtach A, De Smedt S, Lentacker I, Krysko D. Nanomedicine to aid immunogenic cell death (ICD)-based anticancer therapy. TRENDS IN CANCER. 2024;10(6):486–9.
IEEE
[1]
R. Demuynck, Y. Engelen, A. Skirtach, S. De Smedt, I. Lentacker, and D. Krysko, “Nanomedicine to aid immunogenic cell death (ICD)-based anticancer therapy,” TRENDS IN CANCER, vol. 10, no. 6, pp. 486–489, 2024.
@article{01J06C8SQNA973BC9XA18051AA,
  abstract     = {{Immunogenic cell death (ICD) is emerging as a key component of antitumor therapy that harnesses the immune system of the patient to combat cancer. In recent years, several efforts were made to improve the ICD-based therapies. Here, we discuss how nanomaterial-based strategies increase the efficacy of ICD and highlight their benefits and challenges.}},
  author       = {{Demuynck, Robin and Engelen, Yanou and Skirtach, Andre and De Smedt, Stefaan and Lentacker, Ine and Krysko, Dmitri}},
  issn         = {{2405-8025}},
  journal      = {{TRENDS IN CANCER}},
  keywords     = {{DAMPs,anticancer immunity,apoptosis,necroptosis,pyroptosis and ferroptosis nanoparticles,immunogenic cell death,nanomedicine,nanoparticles,nanocapsules,anticancer therapy,cancer,CANCER}},
  language     = {{eng}},
  number       = {{6}},
  pages        = {{486--489}},
  title        = {{Nanomedicine to aid immunogenic cell death (ICD)-based anticancer therapy}},
  url          = {{http://doi.org/10.1016/j.trecan.2024.03.003}},
  volume       = {{10}},
  year         = {{2024}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: